TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34488691

Group type: EXPERIMENTAL
Intervention: Bundle 1 (Basic)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Bundle 1 + 2 (Enhanced)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 1400
Study: 34365570

Group type: EXPERIMENTAL
Intervention: Conventional etching (CE) with pit and fissure sealants (PFS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Self-etching (SE) agent 1 with PFS (SE1_PFS_Shofu)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Self-etching (SE) agent with PFS (SE_PFS_Kuraray)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All experimental groups with PFS
Number of subjects: 25
Study: 33819223

Group type: EXPERIMENTAL
Intervention: Classic Laryngeal Mask Airway (cLMA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Suprema Laryngeal Mask Airway (sLMA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Height/thyromental distance ratio
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall predictive tests
Number of subjects: 120
Study: 33197271

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg/weekly)
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study: 36477889

Group type: EXPERIMENTAL
Intervention: 1.83 g protein kg body mass−1 day−1 (HIGH)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1.20 g protein kg body mass−1 day−1 (MOD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.94 g protein kg body mass−1 day−1 (LOW)
Number of subjects: 9
Study: 32582177

Group type: EXPERIMENTAL
Intervention: HCMV+ infants
Number of subjects: 225

Group type: COMPARATOR
Intervention: HCMV- infants
Number of subjects: 225
Study: 32075475

Group type: EXPERIMENTAL
Intervention: ASP1707 30 mg twice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 33004310

Group type: EXPERIMENTAL
Intervention: Usual care plus financial incentives (up to $1000 contingent on individual reduction of tobacco usage)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care (TSE education and quitline referrals)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intervention cohort's caregivers
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Paired social network members in intervention cohort
Number of subjects: 135
Study: 32715623

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) with albumin replacement
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo (sham)
Number of subjects: 347
Study: 34579560

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Propranolol (160 mg/day)
Number of subjects: 175
Study: 34115064

Group type: EXPERIMENTAL
Intervention: Allogeneic bone substitute
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Xenogeneic bone substitute
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (incubated leukocytes only)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alloplastic bone substitute
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Different masses of bone substitute (12.5 mg and 25 mg)
Number of subjects: 10
Study: 35209731

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 17073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17073
Study: 32521096

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Seeking Safety (SS)
Number of subjects: 119
Study: 34607285

Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (four cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs
Number of subjects: 0
Study: 32171815

Group type: EXPERIMENTAL
Intervention: Educational video and patient information leaflet targeting misconceptions of topical corticosteroids
Number of subjects: 275
Study: 35332505

Group type: EXPERIMENTAL
Intervention: Hand‐Held‐Skin‐to‐Skin (HHS)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Hand‐Held‐Skin‐to‐Glove (HHG)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Hand‐not‐Held (HNH)
Number of subjects: 195
Study: 32185840

Group type: EXPERIMENTAL
Intervention: ART with protease inhibitors (PI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: ART without protease inhibitors (PI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ART with protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Number of subjects: 88

Group type: COMPARATOR
Intervention: ART without protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 36509889

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 33755091

Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 80
Study: 33734883

Group type: EXPERIMENTAL
Intervention: Vandenberg and Kuse Mental Rotation Test (MRT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Higher anatomy knowledge
Number of subjects: 39

Group type: COMPARATOR
Intervention: Other parameters
Number of subjects: 39
Study: 33773357

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for 24 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supportive psychotherapy for 24 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy or supportive psychotherapy
Number of subjects: 120
Study: 36351707

Group type: EXPERIMENTAL
Intervention: Lay counsellor-led problem-solving intervention supported by printed materials
Number of subjects: 32

Group type: COMPARATOR
Intervention: Printed problem-solving materials alone (bibliotherapy)
Number of subjects: 32
Study: 33466136

Group type: EXPERIMENTAL
Intervention: Care of Parkinson disease nurse specialist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35816306

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection and exercise therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection and exercise therapy
Number of subjects: 100
Study: 34089525

Group type: EXPERIMENTAL
Intervention: Induction of labour (IOL)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Expectant care (Control)
Number of subjects: 160
Study: 32858145

Group type: EXPERIMENTAL
Intervention: Right anode tDCS (RA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Left anode tDCS (LA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study: 34221476

Group type: EXPERIMENTAL
Intervention: Laser Auricular Acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser Auricular Acupuncture with Counselling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Psychological Counselling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (No intervention specified)
Number of subjects: 60
Study: 32271146

Group type: EXPERIMENTAL
Intervention: Pure aerobic exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined aerobic resistance exercise
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (usual treatment)
Number of subjects: 45
Study: 35550356

Group type: EXPERIMENTAL
Intervention: r-ESWT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 30
Study: 34086195

Group type: EXPERIMENTAL
Intervention: Pre-DGA attendance for examination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Post-DGA attendance for examination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pre-DGA attendance at emergency appointments
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Post-DGA attendance at emergency appointments
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preventative intervention over 24 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Provision of operative treatment post-DGA
Number of subjects: 80
Study: 36304817

Group type: EXPERIMENTAL
Intervention: FF-20 (1000 mg, delivering 192 mg fisetin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: UF (1000 mg)
Number of subjects: 15
Study: 33025926

Group type: COMPARATOR
Intervention: Insulin Syringe (IS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Auto-Controlled Syringe (ACS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both IS and ACS
Number of subjects: 80
Study: 33306564

Group type: EXPERIMENTAL
Intervention: Smart-pill bottle service
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Smart-pill bottle service (after excluding 3 participants with drug-drug interactions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control arms (after excluding 3 participants with drug-drug interactions)
Number of subjects: 63
Study: 33076932

Group type: EXPERIMENTAL
Intervention: Numerical risk information (risk categories of one in 40, one in 1600 and one in 3500)
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Categorical risk information (highest, moderate and lowest risk)
Number of subjects: 2767

Group type: COMPARATOR
Intervention: Positive screening result letter (control group)
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: All groups (numerical, categorical, control)
Number of subjects: 2767
Study: 36041732

Group type: EXPERIMENTAL
Intervention: Fructose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose and rice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose and rice
Number of subjects: 8
Study: 33772433

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (3 mL of 3.2% MgSO4 every 4 hours for 24 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 60
Study: 32591823

Group type: EXPERIMENTAL
Intervention: Chemo+surgery
Number of subjects: 218

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 218
Study: 35333024

Group type: EXPERIMENTAL
Intervention: Usual care and up to 8 individual consultations with a specialist in sexual counseling
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study: 32253548

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (TXA) administered before incision, 3, 6, 12, 18, and 24 hours later (Group D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (TXA) (Group D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TXA (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (including Group D)
Number of subjects: 0
Study: 34967670

Group type: EXPERIMENTAL
Intervention: Victim resistance in date rapes involving male victims
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Victim gender and victim resistance
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Rape type and victim gender
Number of subjects: 622
Study: 33392930

Group type: EXPERIMENTAL
Intervention: Preference trial (PCT)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Partially randomized patient preference trial (PRPPT)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 416
Study: 33119884

Group type: EXPERIMENTAL
Intervention: Lung metastasectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no metastasectomy)
Number of subjects: 0
Study: 32498372

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS), three times daily for six months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 33451648

Group type: EXPERIMENTAL
Intervention: High-density peptide arrays screening of twelve leading vaccine candidates as overlapping 15-mer peptides.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bioinformatics approach to predict immunogenic malaria epitopes validated in the assay.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Randomly selected peptides from the malaria proteome as a control.
Number of subjects: 27
Study: 34928484

Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg intravenously every 2 weeks) plus Erlotinib (150 mg/day orally)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (150 mg/day orally)
Number of subjects: 446
Study: 32336587

Group type: EXPERIMENTAL
Intervention: 20° lateral view
Number of subjects: 124

Group type: COMPARATOR
Intervention: 0° lateral view
Number of subjects: 124
Study: 36881395

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapies (GDMT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 34189606

Group type: EXPERIMENTAL
Intervention: Oral Health Education and Prevention Program (OHEPP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no educational interventions)
Number of subjects: 28
Study: 32711612

Group type: EXPERIMENTAL
Intervention: NAB PC (albumin‐binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PC (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NAB PC
Number of subjects: 60

Group type: COMPARATOR
Intervention: PC
Number of subjects: 60
Study: 35440448

Group type: EXPERIMENTAL
Intervention: Infant tummy time intervention group (practice, education, WhatsApp) plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study: 32950674

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Corticosteroid Injection (CS)
Number of subjects: 101
Study: 34976652

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children – for Caregivers (ICC‐C) intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 203
Study: 34448685

Group type: EXPERIMENTAL
Intervention: Specialised Content Knowledge (SCK) training
Number of subjects: 216

Group type: COMPARATOR
Intervention: Common Content Knowledge (CCK) training
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: SCK training
Number of subjects: 216
Study: 33407492

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting adverse outcomes including heart rate, systolic pressure, N-terminal-pro brain natriuretic peptide, and ventricle/atrial diameter ratios at 4-chamber view.
Number of subjects: 845
Study: 34151667

Group type: EXPERIMENTAL
Intervention: Supervised Pilates (n=4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Home-based Pilates (n=6)
Number of subjects: 10
Study: 33340400

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monitoring Only (MO)
Number of subjects: 40
Study: 36053506

Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 26 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 9 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 26 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 9 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study: 33159424

Group type: COMPARATOR
Intervention: Belgium cohort (n=30)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Guinea cohort (n=91)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MRI analysis of prospective cohort (n=30)
Number of subjects: 121
Study: 35453124

Group type: EXPERIMENTAL
Intervention: Compression garment group (shin splints compression wrap during waking hours for 2 weeks, then during activity for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relative rest group
Number of subjects: 0
Study: 34023009

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg plus topical corticosteroids
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg plus topical corticosteroids
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids
Number of subjects: 901
Study: 35665810

Group type: EXPERIMENTAL
Intervention: GAD-alum (4 μg) with oral vitamin D
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 32791011

Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet (KD) utilizing medium chained triglyceride fats during a four-month period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Institutionalized standard traditional diet
Number of subjects: 0
Study: 35940560

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 3g administered intra-articular after cementation and prior to capsular closure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA) and Placebo
Number of subjects: 150
Study: 33844449

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg once daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 304
Study: 34323666

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study: 35126208

Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH) service in Zurich providing targeted, individual and flexible support for housing problems
Number of subjects: 58

Group type: COMPARATOR
Intervention: Regular housing and support services currently available (Control Group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH) service
Number of subjects: 58
Study: 34415475

Group type: EXPERIMENTAL
Intervention: Post-ablation acute surface P wave morphology and electrocardiographic parameters
Number of subjects: 160
Study: 33129819

Group type: EXPERIMENTAL
Intervention: iFR pullback
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RFR pullback
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: dPR pullback
Number of subjects: 150

Group type: COMPARATOR
Intervention: NHPR pullback strategy
Number of subjects: 150
Study: 33270316

Group type: EXPERIMENTAL
Intervention: Acoustic markers (F0 span, speech rate, pause proportion, jitter)
Number of subjects: 38
Study: 35986825

Group type: EXPERIMENTAL
Intervention: Upfront incentive ($2)
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Response-based incentive ($10 conditional)
Number of subjects: 2830
Study: 34871061

Group type: EXPERIMENTAL
Intervention: 0/1-hour high-sensitivity troponin T protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: masked 0/3-hour high-sensitivity troponin T protocol
Number of subjects: 0
Study: 35992204

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Physician adjustment (Control)
Number of subjects: 9
Study: 32351118

Group type: EXPERIMENTAL
Intervention: SUVN-G3031
Number of subjects: 0
Study: 35972165

Group type: EXPERIMENTAL
Intervention: Preoperative 8-mg dexamethasone
Number of subjects: 600

Group type: COMPARATOR
Intervention: 0.9% NaCl as control
Number of subjects: 600
Study: 36050610

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 130
Study: 34419100

Group type: EXPERIMENTAL
Intervention: Inexperienced observers (medical students)
Number of subjects: 4
Study: 32933332

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35106935

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control (no ICD)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Coronary atherosclerosis presence
Number of subjects: 838
Study: 32592218

Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Elliptical cross-trainer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Arm ergometer
Number of subjects: 15
Study: 32506738

Group type: EXPERIMENTAL
Intervention: Maribavir 100 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Maribavir 1200 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Maribavir (both doses)
Number of subjects: 52
Study: 34802065

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CPAP+LCKD
Number of subjects: 70
Study: 32517564

Group type: EXPERIMENTAL
Intervention: Rape myth intervention (treatment group)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Unrelated video content (control group)
Number of subjects: 137
Study: 34814766

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment during chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 20
Study: 36574401

Group type: EXPERIMENTAL
Intervention: Psychological rehabilitation program
Number of subjects: 109
Study: 33194212

Group type: EXPERIMENTAL
Intervention: Pragmatic cluster randomized trials in hemodialysis
Number of subjects: 19
Study: 36054921

Group type: COMPARATOR
Intervention: Daridorexant (exact dosage and duration not specified)
Number of subjects: 602
Study: 32993544

Group type: EXPERIMENTAL
Intervention: Infant Feeding Genogram delivered to the intervention group (n=50)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Infant Feeding Genogram
Number of subjects: 103